Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Tissue Fibrosis Decoded via Cellular Senescence: Mechanisms, Treatments, and Emerging Technologies

Cai W., Zhang H., Li Z., Cai M., Yu S., Chen P.

Narrative Review on Systemic / IV, published in Aging Dis (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Aging Dis (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40768641
PMCID
PMC13256446
DOI
10.14336/ad.2025.0503
Citations
1

Abstract (original English)

Cellular senescence is one of the hallmarks of aging, and it is closely related to tissue fibrosis in various age-related diseases. By integrating multi-level and multi-dimensional data, emerging technologies can comprehensively analyze the complex mechanisms of aging and fibrosis diseases, discover new biomarkers and therapeutic targets, and promote the development of precision medicine. Most of the current reviews still focus on the molecular mechanisms of cellular senescence and fibrosis diseases, but lack a comprehensive summary of anti-aging drugs for the treatment of fibrosis-related diseases, and emerging technologies and integrated analysis of multi-omics data. This review discusses the latest evidence on the role of cellular senescence in tissue fibrosis, especially lungs, liver, and kidney fibrosis. In addition, we also introduce the application of anti-aging strategies in fibrotic diseases, especially drugs to eliminate senescent cells, and the latest application of emerging technologies in aging and fibrotic diseases.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHumansFibrosisAgingBiomarkersCellular Senescence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research